1.The effects of cromakalim on the mediator releases from guinea pig lung mast cell activated by specific antigen-antibody reactions.
Jai Youl RO ; Young Nae YIM ; Kyung Hwan KIM
Yonsei Medical Journal 1996;37(5):325-338
The inhibitory effect of cromakalim on the mediator release from mast cells caused by antigenantibody reactions was in controversy with the specific antigen used. However, it has recently been observed that cromakalim inhibits the release of mediators from superfused tracheal and parenchymal strips or lung mast cells after passive sensitization with the IgG1 antibody. An attempt, therefore, was made to determine the inhibitory mechanisms of cromakalim on the release of mediators such as histamine and leukotriene released by the activation of enzymes during mast cell activation. Guinea pig lung mast cells were purified through enzyme digestion, rough percoll and continuous percoll density gradients. The purified mast cells were prelabeled with [3H]palmitic acid. PLD activity was assessed more directly by the production of labeled phosphatidylethanol by PLD-mediated transphosphatidylation in the presence of ethanol. In the cells labelled with [3H]myristic acid, [3H] DAG production was measured. The methyltransferase activity was assessed by measuring the incorporation of [3H]methyl moiety into phospholipids in sensitized mast cells labelled with L-[3H] methylmethionine. cAMP level was measured by radioimmunoassay. Cromakalim resulted in a decrease in the amount of histamine and leukotrienes releases by 30% in the ovalumin-induced mast cell. Cromakalim had little effect on phospholipase D activity enhanced by the activated mast cell. Cromakalim inhibited the initial increase of diacylglycerol production during mast cell activations. Cromakalim inhibited the phospholipid methylation increased in the activated mast cell. These results show that cromakalim decreases histamine release by inhibiting the initial increase of 1,2-diacylglycerol during the mast cell activation, which is mediated via the phosphatidylinositide-phospholipase C system rather than the phosphatidylcholine-phospholipase D system. Furthermore, cromakalim reduces phosphatidylcholine production by inhibiting the methyltransferase, which decreases the conversion of phosphatidylcholine into arachidonic acid and inhibits the production of leukotrienes.
Adenylate Cyclase/metabolism
;
Animal
;
*Antigen-Antibody Reactions
;
Benzopyrans/*pharmacology
;
Cromakalim
;
Diglycerides/biosynthesis
;
Female
;
Guinea Pigs
;
Histamine Release/*drug effects
;
Leukotrienes/*secretion
;
Lung/drug effects/secretion
;
Mast Cells/*drug effects/secretion
;
Methylation
;
Phospholipase D/metabolism
;
Phospholipids/metabolism
;
Potassium Channels/*drug effects
;
Pyrroles/*pharmacology
;
Support, Non-U.S. Gov't
2.The effects of cromakalim on the mediator releases from guinea pig lung mast cell activated by specific antigen-antibody reactions.
Jai Youl RO ; Young Nae YIM ; Kyung Hwan KIM
Yonsei Medical Journal 1996;37(5):325-338
The inhibitory effect of cromakalim on the mediator release from mast cells caused by antigenantibody reactions was in controversy with the specific antigen used. However, it has recently been observed that cromakalim inhibits the release of mediators from superfused tracheal and parenchymal strips or lung mast cells after passive sensitization with the IgG1 antibody. An attempt, therefore, was made to determine the inhibitory mechanisms of cromakalim on the release of mediators such as histamine and leukotriene released by the activation of enzymes during mast cell activation. Guinea pig lung mast cells were purified through enzyme digestion, rough percoll and continuous percoll density gradients. The purified mast cells were prelabeled with [3H]palmitic acid. PLD activity was assessed more directly by the production of labeled phosphatidylethanol by PLD-mediated transphosphatidylation in the presence of ethanol. In the cells labelled with [3H]myristic acid, [3H] DAG production was measured. The methyltransferase activity was assessed by measuring the incorporation of [3H]methyl moiety into phospholipids in sensitized mast cells labelled with L-[3H] methylmethionine. cAMP level was measured by radioimmunoassay. Cromakalim resulted in a decrease in the amount of histamine and leukotrienes releases by 30% in the ovalumin-induced mast cell. Cromakalim had little effect on phospholipase D activity enhanced by the activated mast cell. Cromakalim inhibited the initial increase of diacylglycerol production during mast cell activations. Cromakalim inhibited the phospholipid methylation increased in the activated mast cell. These results show that cromakalim decreases histamine release by inhibiting the initial increase of 1,2-diacylglycerol during the mast cell activation, which is mediated via the phosphatidylinositide-phospholipase C system rather than the phosphatidylcholine-phospholipase D system. Furthermore, cromakalim reduces phosphatidylcholine production by inhibiting the methyltransferase, which decreases the conversion of phosphatidylcholine into arachidonic acid and inhibits the production of leukotrienes.
Adenylate Cyclase/metabolism
;
Animal
;
*Antigen-Antibody Reactions
;
Benzopyrans/*pharmacology
;
Cromakalim
;
Diglycerides/biosynthesis
;
Female
;
Guinea Pigs
;
Histamine Release/*drug effects
;
Leukotrienes/*secretion
;
Lung/drug effects/secretion
;
Mast Cells/*drug effects/secretion
;
Methylation
;
Phospholipase D/metabolism
;
Phospholipids/metabolism
;
Potassium Channels/*drug effects
;
Pyrroles/*pharmacology
;
Support, Non-U.S. Gov't
3.Leukotriene and respiratory syncytial virus.
Chinese Journal of Pediatrics 2013;51(2):109-110
Acetates
;
administration & dosage
;
therapeutic use
;
Asthma
;
drug therapy
;
etiology
;
metabolism
;
Bronchiolitis, Viral
;
drug therapy
;
Cysteine
;
metabolism
;
Humans
;
Infant
;
Infant, Newborn
;
Leukotriene Antagonists
;
administration & dosage
;
therapeutic use
;
Leukotrienes
;
biosynthesis
;
Nasopharynx
;
secretion
;
Quinolines
;
administration & dosage
;
therapeutic use
;
Respiratory Syncytial Virus Infections
;
drug therapy
;
metabolism
;
virology
;
Risk Factors
4.The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model.
M Hamdi MUZ ; Figen DEVECI ; Yasemin BULUT ; Nevin ILHAN ; Hayrettin YEKELER ; Teyfik TURGUT
Experimental & Molecular Medicine 2006;38(2):109-118
Airway structural changes that occur in patients with asthma in response to persistent inflammation are termed airway remodeling. The cysteinyl leukotrienes (LTC4, D4 and E4) are known to play important roles in the pathobiology of asthma. To evaluate the effect of low dose montelukast (MK) on the development of airway remodeling using a chronic murine model of allergic airway inflammation with subepithelial fibrosis, BALB/c mice, after intraperitoneal ovalbumin (OVA) sensitization on days 0 and 14, received intranasal OVA periodically on days 14-75. MK treated mice received montelukast sodium intraperitoneally on days 26-75. The OVA sensitized/challenged mice developed an extensive eosinophil cell inflammatory response, goblet cell hyperplasia, mucus occlusion, and smooth muscle hypertrophy of the airways. In addition, in OVA sensitized/challenged mice, dense collagen deposition/fibrosis was seen throughout the lung interstitium surrounding the airways, blood vessels, and alveolar septae. The cysteinyl leukotriene 1 (CysLT1) receptor antagonist, MK significantly reduced the airway eosinophil infiltration, goblet cell hyperplasia, mucus occlusion, and lung fibrosis except airway smooth muscle hypertrophy in the OVA sensitized/challenged mice. The OVA sensitized/challenged mice had significantly increased epithelial desquamation compared with control mice. MK markedly reduced epithelial desquamation of airways in OVA/MK treated animals compared with OVA sensitized/challenged mice. MK treatment did not affect the levels of CysLT in lung tissue. Our results show that the important role of cysteinyl leukotrienes in the pathogenesis of asthma. Lower dose of CysLT1 receptor antagonism has a significant anti-inflammatory effect on allergen-induced lung inflammation and fibrosis but not airway smooth muscle hypertrophy in an animal model of asthma.
Respiratory Mucosa/pathology
;
Receptors, Leukotriene/metabolism
;
Quinolines/*therapeutic use
;
Pulmonary Fibrosis/pathology
;
Muscle, Smooth/pathology
;
Mucus/secretion
;
Mice, Inbred BALB C
;
Mice
;
Lung/pathology
;
Leukotrienes/*biosynthesis
;
Leukotriene Antagonists/*therapeutic use
;
Hypertrophy
;
Hyperplasia
;
Goblet Cells/pathology
;
Drug Evaluation, Preclinical
;
Dose-Response Relationship, Drug
;
Disease Models, Animal
;
Cysteine/*biosynthesis
;
Collagen/metabolism
;
Asthma/*drug therapy/metabolism/pathology
;
Anti-Asthmatic Agents/*therapeutic use
;
Animals
;
Airway Obstruction/drug therapy/pathology
;
Acetates/*therapeutic use